shuo ma md phd

Professor, Medicine (Hematology and Oncology)

• Northwestern Medicine Doctor Profile

Institutes and Centers

• Robert H. Lurie Comprehensive Cancer Center

Shuo Ma, MD, PhD

Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine

Research Program

• Translational Research in Malignancy (TRIM)

shuo-ma( at )northwestern.edu

Cancer-Focused Research

Dr. Ma directs the clinical and translational research initiatives in chronic lymphocytic leukemia (CLL) to develop and study novel treatment agents for the treatment of CLL. Her translational investigations have included novel biologic agents, mechanisms of drug resistance and immunotherapy. Dr. Ma is the Principal Investigator for a number of investigator-initiated and industry-sponsored clinical trials studying new exciting treatments agents for CLL and lymphoma. She collaborates with investigators at Northwestern University, other US institutions and international institutions in developing novel therapeutic approaches in hematologic malignancies.

• Help & FAQ

View Scopus Profile

• Professor , Medicine, Hematology Oncology Division
• Member , Robert H. Lurie Comprehensive Cancer Center
• 4378 Citations
• 3522 Citations
• 1093 Citations

Research activity per year

Personal profile

Research interests.

Dr. Ma' clinical and research interests are focused on chronic lymphoid malignancies,including chronic lymphocytic leukemia and non-Hodgkin lymphoma. Dr. Ma directs the clinical and translational research initiatives in chronic lymphocytic leukemia (CLL) to develop and study novel treatment agents for the treatment of CLL. Her translational investigations have included novel biologic agents, mechanisms of drug resistance and immunotherapy. Dr. Ma is the Principal Investigator for a number of investigator-initiated and industry-sponsored clinical trials studying new exciting treatments agents for CLL and lymphoma. She collaborates with investigators at Northwestern University, other US institutions and international institutions in developing novel therapeutic approaches in hematologic malignancies.

Certifications and Licenses

Training Experience

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

Education/Academic qualification

PhD, Northwestern University

MD, Medicine, Beijing Medical University

Research interests keywords

• Biologic Therapies
• Blood Cancer (leukemia and lymphomas)
• Chronic Lymphocytic Leukemia
• Non-Hodgkin's Lymphoma

Fingerprint

• 6 Similar Profiles
• patients INIS 100%
• leukemia INIS 97%
• Chronic Lymphatic Leukemia Pharmacology, Toxicology and Pharmaceutical Science 71%
• lymphomas INIS 71%
• Patient Medicine and Dentistry 70%
• B-Cell Chronic Lymphocytic Leukemia Medicine and Dentistry 68%
• therapy INIS 56%
• Therapeutic Procedure Medicine and Dentistry 53%

Collaborations and top research areas from the last five years

Dive into details.

Select a country/territory to view shared publications and projects

• 22 Finished

Grants per year

Prot #C1763102: A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Worldwide Clinical Trials, Inc. , Carna Biosciences, Inc.

4/19/24 → 4/19/27

Project : Research project

Prot #M20-638: A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCCORE™ FL-1)

AbbVie Inc.

10/12/23 → 10/12/24

Prot #IGM-2323-001: A Phase 1/2 Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas

Covance Inc. , IGM Biosciences, Inc.

4/10/23 → 4/10/26

Prot #NU MSK20H06: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study of Ibrutinib in Combination With Rituximab in Subjects With Treatment Naïve Marginal Zone Lymphoma

Memorial Sloan-Kettering Cancer Center , Pharmacyclics, Inc.

10/12/22 → 10/12/25

Prot #BGB-11417-101: A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies

DrugDev Inc. , BeiGene Ltd.

8/5/21 → 8/5/24

Research Output

• 9 Review article
• 2 Comment/debate
• 2 Editorial
• 1 Short survey

Research Output per year

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia

Research output : Contribution to journal › Article › peer-review

• B-Cell Chronic Lymphocytic Leukemia 100%
• Venetoclax 100%
• Patient 100%
• Ublituximab 100%
• Umbralisib 100%

Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study

• Observational Study 100%
• Lymphoma 100%
• Humoral Immunity 100%
• COVID-19 Vaccination 100%

Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma

• Mantle Cell Lymphoma 100%
• Ibrutinib 100%
• Inpatient 100%
• Therapeutic Procedure 100%
• patients 100%

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

• Lymphocytic Lymphoma 100%
• Chronic Lymphocytic Leukemia 100%
• Lisocabtagene Maraleucel 100%

Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study

Research output : Contribution to journal › Letter › peer-review

• Cohort Analysis 100%
• Cell Therapy 100%
• Cytokine Release Syndrome 100%
• Central Nervous System 100%

News Center

Immunotherapy improves remission for relapsed, refractory leukemia .

A single infusion of chimeric antigen receptor T-cell (CAR-T) therapy induced complete response or remission in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to a recent clinical trial published in The Lancet.   

“CAR-T therapy uses the patient’s own immune cells to fight cancer. This novel form of cellular immunotherapy has been a major advance in the treatment of relapsed B-cell lymphomas. Here we reported the first multi-center study of Liso-cel, a CAR-T therapy in CLL/SLL,” said Shuo Ma, MD, ‘00 PhD , professor of Medicine in the Division of Hematology and Oncology and a co-author of the study.  

CLL and SLL are essentially the same disease, and is the most common type of leukemia in adults. Both CLL and SLL are caused by cancerous white bloods cells called lymphocytes. In CLL, the lymphocytes originate in bone marrow and in SLL, they’re found in the lymph nodes.   

The landscape for CLL/SLL treatment has evolved significantly over the past decade, with oral targeted therapies (BTK inhibitors and Bcl-2 inhibitors) replacing conventional immunochemotherapy to become the new standard of care.  

Although these targeted therapies are highly effective in CLL/SLL, there are high-risk patients who eventually become refractory, or resistant, to the treatment. Patients who’ve failed both classes of targeted therapies (double-refractory CLL/SLL) are left with few treatment options and poor outcomes, underscoring a need for better treatments.  

In the current study, investigators aimed to evaluate the efficacy and safety of a CAR T-cell therapy, specifically lisocabtagene maraleucel (liso-cel), in 117 adult patients with relapsed or refractory CLL or SLL who received an average of five previous lines of therapy. CAR T-cell therapy employs genetically enhanced T-cells to locate and destroy cancer cells more effectively.  

For the trial, all patients received a one-time intravenous infusion of liso-cel at one of two dosage levels. Among the 49 patients with double-refractory CLL/SLL who received the higher dosage, the overall response rate was 47 percent, and the complete response and remission rate was 18 percent, comparing favorably to a historical rate of zero to 5 percent, according to Ma.

Time to response was about one month and of the patients who achieved complete response and remission, none had relapsed at a 20-month follow up, indicating the durability of the response, according to the authors.  

Transient immune-related adverse effects were commonly observed after the liso-cel treatment. More significant (grade 3) adverse events including cytokine release syndrome (an acute systemic inflammatory syndrome) were reported in 9 percent of patients, and advanced neurological events were reported in 18 percent of patients.  

Overall, the findings suggest that a one-time infusion of liso-cel can induce a rapid and durable response in patients with relapsed and refractory CLL or SLL who have exhausted other treatment options, Ma said.

“CAR-T therapy is a very promising future treatment option for our patients with CLL/SLL. Future studies are being planned to compare this novel treatment with the existing standard treatments,” said Ma, who is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.  

This study was funded by Juno Therapeutics, a BMS Company. 

Related Posts

Antioxidant gel preserves islet function after pancreas removal, new glioblastoma treatment reaches human brain tumor and helps immune cells recognize cancer cells, utilizing electronic alerts to help control blood pressure.

Comments are closed.

Type above and press Enter to search. Press Esc to cancel.

Professor, Medicine (Hematology and Oncology)

• Northwestern Medicine Doctor Profile

Institutes and Centers

• Robert H. Lurie Comprehensive Cancer Center

Shuo Ma, MD, PhD

Dr. Ma's clinical and research interests are focused on chronic lymphoid malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHL). Dr. Ma directs the clinical and translational research initiatives in chronic lymphocytic leukemia (CLL) to develop and study novel treatment agents for the treatment of CLL. Her translational investigations have included novel biologic agents, mechanisms of drug resistance and immunotherapy. Dr. Ma is the Principal Investigator for a number of investigator-initiated and industry-sponsored clinical trials studying new exciting treatments agents for CLL and lymphomas. She collaborates with investigators at Northwestern University, other US institutions and international institutions in developing novel therapeutic approaches in hematologic malignancies.

Who Should Not Receive BTK Inhibitors?

A Patient Power user asked which type of patient with chronic lymphocytic leukemia (CLL) is not a good candidate for BTK inhibitors. Our expert responded.

What to Expect from BTK Inhibitors

Who are BTK inhibitors right for, and what changes can you expect from starting treatment? Learn more.

How to Know When “Watch and Wait” is Over

What are the advantages of an early CLL diagnosis, and how will I know it is time to start treatment? Find out.

Today’s “Standard” Treatment for CLL

What is the advantage of an early diagnosis and how will my doctor decide what treatment is best for my CLL? An expert breaks down today’s “standard” treatment.

The Current CLL Treatment Landscape & Advocating for Your Care

Experts including CLL specialists and an oncology social worker are featured in this replay of a live Town Hall event.

What Treatments Are Available for Patients With CLL?

Experts explain the frontline treatment options for CLL in an excerpt from a live Town Hall event.

Where Is CAR T-Cell Therapy Leading Us?

Could new clinical trials and increased access to CAR T-cell therapy improve the status of CLL care? Hear experts discuss.

Shuo Ma, MD, PhD

Clinical expertise.

• Chronic Leukemias
• Medical Education: MD, Beijing Medical University - 1994
• Residency: AMITA Health/St Joseph Hospital (Chicago) - 2005
• Fellowships: McGaw Medical Center of Northwestern University - 2008

Languages Spoken

Board certifications.

• American Board of Internal Medicine - Hematology (Certified)
• American Board of Internal Medicine - Internal Medicine (Certified)

Northwestern University Feinberg School Of Medicine: Arkes Pavilion, 676 N St Clair St Ste 850, Chicago, IL 60611, USA

Get the latest thought leadership on Chronic Myelomonocytic Leukemia delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Chronic Myelomonocytic Leukemia Newsletter" for Chronic Myelomonocytic Leukemia news, life with Chronic Myelomonocytic Leukemia stories, Chronic Myelomonocytic Leukemia clinical trials, Chronic Myelomonocytic Leukemia 101 articles and events with Chronic Myelomonocytic Leukemia experts.

Get Involved

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Copyright © 2024 HealthTree Foundation. All rights reserved.

Tax ID 45-5354811

Dr. Shuo Ma Discusses Side Effects from New Treatments in NHL

Shuo Ma, MD, PhD, assistant professor at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center, discusses some of the side effects that come with new agents approved for the treatment of non-Hodgkin Lymphoma.

It is important to know the safety profile of these agents in order to monitor for serious side effects and potential drug interaction, Ma says.

Idelalisib, for example, can cause severe diarrhea. It is important to advise patients, especially elderly patients, to contact their health care providers if they experience any symptoms of severe diarrhea in order to prevent dehydration.

Another novel therapy, ibrutinib, is known to cause an increased risk of bleeding in patients. Therefore, if patients are taking ibrutinib along with anti-coagulation therapies, they should be closely monitored.

Oral Azacitidine Demonstrates Consistent Safety Profile in Lower-Risk MDS

Oral azacitidine had a similar safety profile across the 200-mg and 300-mg groups in lower- to intermediate-risk MDS.

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Identifying and Managing Oral Adverse Effects From Cancer Treatments

Oncology nurses can aid in the identification and management of oral adverse effects from cancer therapies.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Pelabresib Plus Ruxolitinib Significantly Reduces Splenomegaly in Myelofibrosis

Updated data from the MANIFEST-2 study support a paradigm shift in the treatment of JAK inhibitor–naive patients with myelofibrosis.

Brentuximab Vedotin Regimen Improves PFS, QoL Over Chemo in Classical Hodgkin Lymphoma

A brentuximab vedotin-containing regimen led to “unprecedented” progression-free survival improvements in patients with advanced classical Hodgkin lymphoma.

Latest Conference Coverage

Stopping Enzalutamide May Not Impact Quality of Life in Prostate Cancer Subset

Adding Atezolizumab to Chemo/Bevacizumab May Not Be Beneficial in Ovarian Cancer

Adding Tucidinostat to R-CHOP Demonstrates Safety, Efficacy in DLBCL Subtype

2 Commerce Drive Cranbury, NJ 08512

609-716-7777

International Waldenstrom’s Macroglobulinemia Foundation

What is WM?

• What is Waldenstrom’s Macroglobulinemia?
• Causes and Risk Factors
• Prognosis in WM
• Symptoms of WM
• How is WM Diagnosed?
• Getting a Second Opinion
• Glossary of Terms
• Newly Diagnosed?
• Directory of WM Physicians
• When is Treatment Needed for WM?
• Overview of Treatments
• Treatment Regimens and Considerations
• Managing Side Effects of Treatment
• Potential Outcomes of Treatment
• Clinical Trials
• Organize Your Medical Records
• Complementary, Alternative, and Integrative Medicine
• Financial Assistance
• Education Resources
• – IWMF & Affiliate Publications
• – IWMF Torch
• – Specific Topics in the Torch
• – Publications about WM from IWMF Partners
• IWMF Video Channel
• Other Resources for Living with Cancer

Living Well With WM

• Living with WM
• – Emotional Wellness
• – Nutrition & Physical Wellness
• – Yoga
• – T’ai Chi
• – Fitness
• – Relaxation Guidance
• – Wellness Webinars
• Find Support
• US and International Support Groups
• International Affiliates
• IWMF Connect and Online Discussion Forums
• Stories of Hope
• LIFELINE and One-on-One Support
• Support for Caregivers
• IWMF Newsroom
• Waldenstrom’s Weekly Archive
• Calendar of Events
• IWMF Educational Forum
• IWMF Walk for Waldenstrom’s

Researchers

• Research Strategy
• Applying for a Research Grant
• -Current Research Recipients
• -Past Research Recipients

Healthcare Professionals

• Continuing Education Programs
• Resources for Healthcare Professionals
• WM Medical Practice Guidelines & Research Articles
• Ways to Give
• Accelerate the Cure Campaign
• The Ben Rude Heritage Society-Planned Giving
• Fundraise for IWMF
• Create a Facebook Fundraiser
• Walk for Waldenstrom’s Leaderboard
• Shop at the IWMF Store

Participate

• Join the IWMF Community
• Participate in Patient Registries
• Volunteerism for IWMF
• Vision & Mission
• Our History
• Home Office Team
• Officers & Board of Trustees
• Scientific and Research Committees
• Financial Information
• IWMF Media Toolkit
• 6144 Clark Center Ave.Sarasota, FL 34238
• Phone: 941-927-4963
• Fax: 941-927-4467
• [email protected]

Shuo Ma, MD, PhD Presentations

Current Treatment of WM

Shuo MA, MD, PhD – Northwestern University Feinberg School of Medicine, 2018 Ed Forum Provides an overview of WM and IgM related complications, as well as an overview of treatment criteria and currently available active agents for WM

Link to Ma slides

Advertisement

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

• Split-Screen
• Request Permissions
• Cite Icon Cite
• Search Site

Reem Karmali , Jeremy S. Abramson , Deborah M. Stephens , Jeffrey A. Barnes , Jason Kaplan , Jane N. Winter , Shuo Ma , Juehua Gao , Adam M. Petrich , Ephraim Hochberg , Ronald W. Takvorian , Frank Kuhr , Valerie Nelson , Leo I. Gordon , Barbara Pro; Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation. Blood 2019; 134 (Supplement_1): 3990. doi: https://doi.org/10.1182/blood-2019-126920

Download citation file:

• Ris (Zotero)
• Reference Manager

Background: MCL carries a poor overall prognosis despite high response rates to induction chemotherapy. Maintenance strategies have impacted survival in MCL but optimal strategies have yet to be defined. Despite profound activity of ibrutinib, a selective BTK inhibitor, in relapsed/refractory MCL, ibrutinib maintenance (I-M) following induction for treatment-naive MCL has not been explored. We report preliminary results of a multicenter phase II trial assessing efficacy and safety of I-M for MCL after frontline induction.

Methods: Patients (pts) with MCL with complete or partial response (CR/PR) to frontline chemo-immunotherapy +/- autologous stem cell transplantation (autoSCT) received I-M 560 mg daily for up to 4 years. The primary objective was 3 year PFS rate with I-M. Secondary objectives were PR to CR conversions, median OS after 4 years and toxicity. Measurable residual disease (MRD) assessments using an NGS-MRD Assay (detection resolution of < 1 cell per million; Adaptive Biotechnologies) on peripheral blood and/or PBMCs were planned at 4 time points: prior to I-M initiation and at 1, 6 and 18-24 mo(s) after initiation of I-M.

Results: Accrual is complete (n=36). Median age was 60 (range 46-90), 28 pts (78%) were males, 28 (78%) had advanced stage and 9 (25%) had extranodal disease. 18 (50%), 7 (19%) and 11 (31%) had low vs intermediate vs high risk MIPI respectively. For induction, 17 (47%) received bendamustine-rituximab (BR), 18 (50%) a cytarabine-based regimen, and 1 (3%) R-CHOP. 18 (50%) had autoSCT in CR1 prior to enrollment. 33 (92%) and 3 (8%) had CR and PR with induction respectively with 1 PR to CR conversion on I-M. Median follow-up from initiation of induction therapy was 33 mos. With a median follow-up of 24.5 mos from initiation of I-M, 1 pt had disease progression (PD) and 2 others died, 1 from hepatic cholangiocarcinoma 2 years after I-M discontinuation for toxicity (atrial fibrillation) and 1 from unknown cause. 20/36 (56%) pts remain on I-M (median 24 cycles, range 1-52). Sixteen pts discontinued ibrutinib, including 3 for completion of 4 years of I-M. Of the remaining 13 who discontinued, TRAEs accounted for 10 (77%) and the other 3 were for uterine cancer (n=1), PD (n=1), and death of unknown cause (n=1) (Table 1). Atrial fibrillation/atrial flutter accounted for 50% (n=5) of TRAEs that led to I-M discontinuation. 9 (25%) pts required permanent dose reductions for TRAEs with neutropenia (n=3), myalgias (n=2), and fatigue (n=2) being the most common. Collectively, TRAEs led to dose reductions/ interruptions/ discontinuations in 25 (69%) pts. At time of data cut-off, (July 2019), using a trackable dominant clone identified from tissue at diagnosis, MRD was assessed in 12 patients at varying time points (Figure 1). In these 12 pts, 6 were induced with BR, 5 with a cytarabine-based regimen, and 1 with R-CHOP and 5 were consolidated with autoSCT prior to enrollment. Prior to I-M initiation, 9 pts were MRD (-) and 3 had indeterminate MRD status. Indeterminate results corresponded with total cell counts below the level of detection and quantification with our assay. Those with indeterminate MRD status were confirmed to be MRD (-) with subsequent evaluation after 1 month of I-M. 3 of 12 (25%) pts became MRD (+) on I-M. The first reverted back to MRD (-) status and remains MRD (-) with clinical CR on > 3 years of I-M. The second pt was treated with hyperCVAD with PR prior to I-M. This patient required several dose interruptions for neutropenia just prior to MRD detection with clinical PD leading to discontinuation of therapy after 9 months of I-M. The third pt was treated with R-CHOP + autoSCT with PR prior to I-M and maintains a PR despite MRD conversion on > 2 years of I-M. Further analysis of dynamic changes in dominant and non-dominant clones associated with I-M is ongoing.

Conclusions: I-M is feasible in MCL pts who respond to frontline chemo-immunotherapy +/- autoSCT with manageable toxicities consistent with the known safety profile of ibrutinib. Guidelines to discontinue I-M for atrial fibrillation were strictly upheld in this protocol though not typical of current practice. NGS can be used to assess MRD with induction and maintenance therapy and demonstrates that most pts are MRD negative after intensive induction. Longer follow-up, evaluation of dynamic changes in MRD, and PFS and OS data are needed to assess clinical relevance of I-M and importance of MRD status, and may support larger, controlled studies.

Karmali: Gilead/Kite; Juno/Celgene: Consultancy, Speakers Bureau; Takeda, BMS: Other: Research Funding to Institution; Astrazeneca: Speakers Bureau. Abramson: AbbVie Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, EMD Serono Inc, Genentech, Gilead Sciences Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite Pharma Inc, Merck, Novartis, Seattle Gen: Consultancy. Stephens: Karyopharm: Research Funding; Gilead: Research Funding; Acerta: Research Funding. Winter: Merck: Consultancy, Research Funding. Ma: Genentech: Consultancy; Gilead: Research Funding; Astra Zeneca: Consultancy, Research Funding, Speakers Bureau; Acerta: Research Funding; Abbvie: Research Funding; Incyte: Research Funding; Janssen: Consultancy, Speakers Bureau; Kite: Consultancy; Juno: Research Funding; Xeme: Research Funding; Pharmacyclics: Consultancy, Research Funding, Speakers Bureau; Beigene: Research Funding; Bioverativ: Consultancy; Novartis: Research Funding. Petrich: Abbvie: Employment, Equity Ownership. Kuhr: Adaptive Biotechnologies: Employment, Other: shareholder. Gordon: Zylem LLC: Other: co-founder; research in nanoparticles in cancer; Bayer: Other: Advisory Board; Juno/Celgene: Other: Advisory Board, Research Funding; Gilead: Other: Advisory Board. Pro: Takeda: Consultancy, Honoraria, Other: Travel Expenses; Celgene: Consultancy, Honoraria; Kyowa Hakka Kirin: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria, Other: Travel Expenses, Research Funding.

We will discuss results of our trial looking at ibrutinib maintenance in frontline MCL

Author notes

Asterisk with author names denotes non-ASH members.

This feature is available to Subscribers Only

• Previous Article
• Next Article

Email alerts

Affiliations.

• Current Issue
• First edition
• Collections
• Submit to Blood
• About Blood
• Subscriptions
• Public Access
• Permissions
• Blood Classifieds
• Advertising in Blood
• Terms and Conditions

American Society of Hematology

• 2021 L Street NW, Suite 900
• Washington, DC 20036
• TEL +1 202-776-0544
• FAX +1 202-776-0545

ASH Publications

• Blood Advances
• Blood Neoplasia
• Blood Vessels, Thrombosis & Hemostasis
• Hematology, ASH Education Program
• ASH Clinical News
• The Hematologist
• Publications
• Privacy Policy
• Cookie Policy
• Terms of Use

This Feature Is Available To Subscribers Only

Sign In or Create an Account

• In-person and virtual events just for HCPs

• Conferences
• Publications
• Biomarker Consortium

Shuo Ma, MD, PhD, Northwestern University Feinberg School of Medicine

Latest conference coverage.

MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer

Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma

Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer

Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC

2 Commerce Drive Cranbury, NJ 08512

609-716-7777